ClinicalTrials.Veeva

Menu
S

South Texas Accelerated Research Therapeutics | START Mountain Region

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SM08502
SL-172154
AB801
LP-184
Osimertinib
LP-284
ADRX-0405
REC-1245
SGN-B7H4V
FMC-376

Parent organization

This site is a part of South Texas Accelerated Research Therapeutics

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

37 of 45 total trials

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

This study will evaluate the preliminary efficacy of IMP1734 in patients with recurrent advanced/metastatic breast cancer, ovarian cancer and metasta...

Enrolling
Advanced Solid Tumor
Drug: IMP1734

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of...

Enrolling
HER2-positive Breast Cancer
HER2 + Gastric Cancer
Drug: IAM1363

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants w...

Enrolling
Solid Tumor
Drug: Cemiplimab
Drug: BHV-1510

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in...

Enrolling
Advanced Solid Tumor
Drug: GEN1286

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will...

Enrolling
Advanced Solid Tumors with KRAS G12C Mutations
Solid Tumor, Adult
Drug: FMC-376

The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a re...

Enrolling
Advanced Cancer
Drug: AB801
Drug: Docetaxel

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patie...

Enrolling
Solid Tumors
Drug: ADRX-0405

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patie...

Enrolling
Triple Negative Breast Cancer (TNBC)
Urothelial Cancer
Drug: ADRX-0706

The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in part...

Enrolling
Advanced Solid Tumors
Drug: Capecitabine
Drug: Docetaxel

The purpose of this study is to determine the relative bioavailability (rBA; Period 1) and bioequivalence (BE; Period 2 and 3) of various strengths a...

Active, not recruiting
Prostatic Neoplasms
Drug: Niraparib
Drug: Abiraterone Acetate (AA)

The purpose of the study is to test the safety of the medicine called Felmetatug Vedotin alone and with pembrolizumab in participants with solid tumo...

Active, not recruiting
Ovarian Neoplasms
Adenoid Cystic Carcinoma
Drug: Pembrolizumab
Drug: Felmetatug Vedotin

The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic cast...

Active, not recruiting
Inhibitory Checkpoint Molecule
Immunotherapy
Drug: docetaxel
Drug: Prednisone

The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumo...

Enrolling
Uterine Cervical Neoplasms
Ovarian Neoplasms
Drug: carboplatin
Drug: LY4170156

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in parti...

Enrolling
Small-cell Lung Cancer
Melanoma
Biological: MGC026 Dose for Expansion
Biological: MGC026 Dose Escalation

The purpose of this study is to assess the safety and tolerability of mRNA-4106 administered alone and in combination with checkpoint inhibitor (CPI)...

Not yet enrolling
Advanced Solid Tumors
Biological: Nivolumab/Relatlimab
Biological: mRNA-4106

The purpose of this study is to assess the safety and tolerability of mRNA-4106 administered alone and in combination with checkpoint inhibitor (CPI)...

Enrolling
Advanced Solid Tumors
Biological: Nivolumab/Relatlimab
Biological: mRNA-4106

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.

Enrolling
Endometrial Cancer
Breast Cancer
Drug: Pembrolizumab
Drug: IDE-161

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2...

Enrolling
Solid Tumor
Drug: PT0253

This is a multi-center, open-label study to investigate the safety, tolerability, PK, PD, and preliminary activity of REC-1245 administered orally on...

Enrolling
Locally Advanced
Metastatic Cancers
Drug: REC-1245

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of...

Enrolling
Carcinoma, Non-Small-Cell Lung
Pancreatic Ductal Adenocarcinoma
Drug: bevacizumab
Drug: PF-08046050

Trial sponsors

Lilly logo
S
A
B
Genmab logo
L
MacroGenics logo
Moderna logo
Pfizer logo
Seagen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems